RxDoctor Payments Data

Vijay Divakaran, MD

Interventional Cardiology · Round Rock, TXNPI 1366695074

Payments from drug & device makers

$41,407in general payments, 2019–2025

Across 271 payments — averaging $152.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$19K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$10K
  • Abbott$4K
  • Medtronic$2K
  • Shockwave Medical, Inc$1K
  • Boston Scientific$1K
  • plus $4K from 26 others

What the payments were for

  • Travel & lodging$3,03124%
  • Food & beverage$9,82876%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,407 in reported general payments places this provider in the 75th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$148,724
Medicare patients
1,354
Services billed
2,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban117$153,305
XareltoRivaroxaban28$42,209
EntrestoSacubitril/Valsartan19$26,560
JardianceEmpagliflozin22$24,532
Repatha SureclickEvolocumab18$21,182
Metoprolol Succinate174$3,298
ClopidogrelClopidogrel Bisulfate206$3,242
Rosuvastatin Calcium170$2,858
Atorvastatin Calcium120$1,568
Carvedilol90$1,467
Losartan Potassium115$1,386
Amiodarone Hcl17$1,208
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$774
Furosemide108$688
Spironolactone52$648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$11$42,20928 claims
NovartisEntresto$24$26,56019 claims
Boehringer IngelheimJardiance$35$24,53222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →